Anna Oleksiak: Is Thrombocytopenia in Critical Cardiac Care HIT?
Anna Oleksiak, Cardiologist at National Institute of Cardiology Stefan Cardinal Wyszyński – National Research Institute, shared a post on LinkedIn:
”At ICCU often patient’s platelets drop…
The clinical question – is this HIT, drugs interaction, mechanical injury, MCS, clotting, sepsis or something else?
But there is not much time for the right decisions.
Here are some pages from Association for Acute CardioVascular Care – ACVC Clinical Decision Making Toolkit, chapter about anticoagulation in critically ill, written by me and Christophe Vandenbriele last year.
Some hot points about heparin-induced thrombocytopenia:
- T Score is the most widely used and well-validated risk-prediction score and has excellent negative predictive value.
- An important problem in diagnosing thrombocytopenia is the exclusion of pseudothrombocytopenia, resulting from platelet agglutination in blood collected in an EDTA.
- HIT should be suspected in patients receiving heparin if, for an unknown reason:
1) the platelet count has decreased by ≥50% from the baseline (even if it is 150,000/µL);
2) ≥5 days have passed since the start of heparin administration;
3) a thromboembolic event has occurred;
4) no other causes of thrombocytopenia are identified.
- UFH conveys a HIT risk 10 times greater than that of LMWH.
- Frequently, post-surgical patients exhibit a unique bimodal pattern of platelet decline.
- Although thrombocytopenia is usually a serious problem in the context of bleeding, the occurrence of HIT type II is associated with a 20-40 fold increase in the risk of venous or arterial thrombosis, with an incidence of thrombosis ranging from 50% to 89% in untreated patients.
- The most common cause of death in patients with HIT is pulmonary embolism, less frequently stroke.
- Typically, the heparin-dependent antibodies fall to undetectable levels after 50 to 85 days.”

Stay updated with Hemostasis Today.
-
Nov 21, 2026, 03:45Aref Ghanaatpisheh: The Role of Systemic Inflammation in Preoperative Deep Vein Thrombosis Risk Assessment
-
Nov 21, 2026, 03:43Dimitrios Hatzichristou: Advancing Standardization and Quality Control in Platelet-Rich Plasma Therapy
-
Nov 21, 2026, 03:15Amirabbas Sheykhalo: Silent Mesenteric Ischemia in Portomesenteric Thrombosis
-
Nov 21, 2026, 02:51Ivone Su: Raising Awareness of Venous Thromboembolism
-
Nov 21, 2026, 02:40Aniqa Gohar: One Heart Conclave – Advancing Integrated Thrombosis Care
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan